1.93
3.98%
-0.08
Stereotaxis Inc stock is currently priced at $1.93, with a 24-hour trading volume of 566.34K.
It has seen a -3.98% decreased in the last 24 hours and a -17.87% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.00 pivot point. If it approaches the $1.93 support level, significant changes may occur.
Previous Close:
$2.01
Open:
$1.99
24h Volume:
566.34K
Market Cap:
$159.50M
Revenue:
$26.77M
Net Income/Loss:
$-20.71M
P/E Ratio:
-7.1481
EPS:
-0.27
Net Cash Flow:
$-9.51M
1W Performance:
-2.53%
1M Performance:
-17.87%
6M Performance:
+16.97%
1Y Performance:
-14.98%
Stereotaxis Inc Stock (STXS) Company Profile
Name
Stereotaxis Inc
Sector
Industry
Phone
314-678-6100
Address
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-12-22 | Initiated | Aegis Capital | Buy |
Jun-23-22 | Initiated | B. Riley Securities | Buy |
Jan-05-22 | Initiated | Craig Hallum | Buy |
Jan-05-22 | Initiated | Loop Capital | Buy |
May-26-21 | Initiated | Piper Sandler | Overweight |
Sep-08-20 | Initiated | Northland Capital | Outperform |
Apr-09-20 | Initiated | Cowen | Outperform |
Apr-07-20 | Initiated | Lake Street | Buy |
View All
Stereotaxis Inc Stock (STXS) Latest News
Stereotaxis receives CE mark certification for devices in Europe - BioWorld Online
BioWorld Online
Paul J. Isaac Purchases 6,000 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) Stock - MarketBeat
MarketBeat
Stereotaxis introduces Genesis System at Penn Presbyterian By Investing.com - Investing.com
Investing.com
Stereotaxis wins updated CE mark for all devices available in Europe - Robot Report
Robot Report
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for ... - GlobeNewswire
GlobeNewswire
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for ... - Yahoo Canada Finance
Yahoo Canada Finance
Stereotaxis Inc Stock (STXS) Financials Data
Stereotaxis Inc (STXS) Revenue 2024
STXS reported a revenue (TTM) of $26.77 million for the quarter ending December 31, 2023, a -4.89% decline year-over-year.
Stereotaxis Inc (STXS) Net Income 2024
STXS net income (TTM) was -$20.71 million for the quarter ending December 31, 2023, a -13.24% decrease year-over-year.
Stereotaxis Inc (STXS) Cash Flow 2024
STXS recorded a free cash flow (TTM) of -$9.51 million for the quarter ending December 31, 2023, a +11.93% increase year-over-year.
Stereotaxis Inc (STXS) Earnings per Share 2024
STXS earnings per share (TTM) was -$0.27 for the quarter ending December 31, 2023, a -3.85% decline year-over-year.
About Stereotaxis Inc
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
Cap:
|
Volume (24h):